Option therapeutic approach for primary breast cancer
dc.contributor.author | Zhukova, T. O. | |
dc.contributor.author | Vasko, L. N. | |
dc.contributor.author | Nestulia, K. I. | |
dc.contributor.author | Aikian, A. Z. | |
dc.contributor.author | Mukovoz, O. E. | |
dc.contributor.author | Жукова, Тетяна Олександрівна | |
dc.contributor.author | Васько, Лариса Миколаївна | |
dc.contributor.author | Нестуля, Катерина Ігорівна | |
dc.contributor.author | Айкян, Артем Завенович | |
dc.contributor.author | Муковоз, Оксана Євгенівна | |
dc.contributor.author | Жукова, Татьяна Александровна | |
dc.contributor.author | Васько, Лариса Николаевна | |
dc.contributor.author | Нестуля, Катерина Игоревна | |
dc.contributor.author | Айкян, Артем Завенович | |
dc.contributor.author | Муковоз, Оксана Евгеньевна | |
dc.date.accessioned | 2021-02-15T08:35:09Z | |
dc.date.available | 2021-02-15T08:35:09Z | |
dc.date.issued | 2020-10 | |
dc.description.abstract | Abstract. The first place in the ranking of oncology and the most acute oncology problem is breast cancer (BC), in the vast majority of women [1,2,3,5,18]. The rate of abstinence is high, and the percentage of patients receiving special therapy is 80.4%. All this indicates a low level of qualified care (Kolesnik O.O., Fedorenko Z.P., 2017). The aim of the study was the desire to study the effectiveness of various schemes of preoperative chemo-radiation therapy with radioimodification in the scheme of complex treatment of primary localized BC. Research results and their discussion. Analyzing 1 year of supervision, it is evident that 35 (83.3%) patients died in the I group, 7 died (16.7%). Patients who did not have a recurrence of the process at 1 year of life 25 (59.92%). In the II group, they died at 1 year - 6 (12.76%), and patients without relapsing 36 (76.59%). Comparing the result clearly that the overall survival of a reliable result was not low, and the rate of recurrence is likely to speak for the benefit of Group II. During second year , another 14 patients died in Group І against 7 group II. In the I survived, 21 (50,0%) were left, of which 17 (40,47%) without relapse were against 34 (72,34%) of the live ones, of which 20 (42,55%) without relapse. Summing up our research, supervision over the results of treatment in two groups, we can say that the remote survival results show the following: For 36 months. The observation formed the number of patients who clearly showed the results of treatment in groups I and II. In group І, overall survival rate was 11 (26,19%), with relapse 4 (9,52%). In the II group, the total number of patients with 3 years of observation was 25 (53,19%), with relapse of 17 (36,17%). Conclusions. The study of the effectiveness of the scheme of neoadjuvant chemo-therapy in combination with radiotherapy and radiomodification (group II) showed a positive trend in survival and relapse rates as well as a satisfactory state in the manifestations of toxicity of HT and radiation manifestations compared with the proposed scheme for group I. | uk_UA |
dc.description.abstract | Изучение эффективности схемы неоад`ювантной химиотерапии в сочетании с лучевой терапией и радиомодификацией (II группа) выявило положительную тенденцию по показателям выживаемости и рецидивирования, а также удовлетворительное состояние в проявлениях токсичности ХТ и проявлений лучевых реакций в сравнении со схемой предложенной І группе. По результатам лечения в обеих группах, можно сказать, что отдаленные результаты выживаемости показывают следующее: на 36 мес. наблюдения: в первой группе общая выживаемость 11 (26,19%), из них с рецидивом 4 (9,52%). Во II группе общее количество больных на 3 год наблюдения 25 (53,19%), с рецидивом 17 (36,17%). | uk_UA |
dc.identifier.citation | Option therapeutic approach for primary breast cancer / T. O. Zhukova, L. N. Vasko, K. I. Nestulia, A. Z. Aikian, O. E. Mukovoz // Colloguium-journal. – 2020. – № 28 (80). – P. 24–27. | uk_UA |
dc.identifier.issn | 2520-6990 | |
dc.identifier.issn | 2520-2480 | |
dc.identifier.uri | https://repository.pdmu.edu.ua/handle/123456789/14871 | |
dc.language.iso | en | uk_UA |
dc.publisher | Colloguium-journal Warszawa, Polska | uk_UA |
dc.relation.ispartofseries | 28; | |
dc.subject | neoadjuvant chemotherapy | uk_UA |
dc.subject | primary inoperable breast cancer | uk_UA |
dc.subject | breast | uk_UA |
dc.subject | multifraction | uk_UA |
dc.subject | radiomodification | uk_UA |
dc.subject | неоадъювантная химиотерапия | uk_UA |
dc.subject | первично-неоперабельный рак грудной железы | uk_UA |
dc.subject | грудная железа | uk_UA |
dc.subject | мультифракционирование | uk_UA |
dc.subject | радиомодификация | uk_UA |
dc.subject | неоад'ювантна хіміотерапія | uk_UA |
dc.subject | первинно-неоперабельний рак грудної залози | uk_UA |
dc.subject | грудна залоза | uk_UA |
dc.subject | мультіфракціювання | uk_UA |
dc.subject | радіомодифікації | uk_UA |
dc.subject.udc | 618.19-006-085 | uk_UA |
dc.title | Option therapeutic approach for primary breast cancer | uk_UA |
dc.title.alternative | Вариант терапевтического подхода для первичного рака молочной железы | uk_UA |
dc.title.alternative | Варіант терапевтичного підходу для первинного раку молочної залози | uk_UA |
dc.type | Article | uk_UA |
Файли
Контейнер файлів
1 - 1 з 1
Ескіз недоступний
- Назва:
- breast_ cancer.pdf
- Розмір:
- 278.92 KB
- Формат:
- Adobe Portable Document Format
Ліцензійна угода
1 - 1 з 1
Ескіз недоступний
- Назва:
- license.txt
- Розмір:
- 4.29 KB
- Формат:
- Item-specific license agreed upon to submission
- Опис: